What is Svastek?
Founded in 2022 by Arita Abrol, Svastek is redefining the standards of respiratory support through its flagship ALLTIP technology. The company addresses a critical gap in patient care by enabling continuous noninvasive ventilation (NIV) alongside simultaneous nutrition delivery. This dual-functionality design significantly enhances clinical efficiency and patient comfort, positioning Svastek as a disruptive force in the medical device landscape. By streamlining complex care protocols, the startup is effectively reducing the burden on healthcare providers while improving outcomes for patients requiring long-term respiratory assistance.
How much funding has Svastek raised?
Svastek has raised a total of $232K across 1 funding round:
Angel/Seed
$232K
Angel/Seed (2025): $232K with participation from IAN fund
Key Investors in Svastek
IAN fund
IAN Fund 1 is a SEBI registered venture capital fund that focuses on facilitating growth for innovative startups through seed and early-stage investments. The fund leverages the strengths of the IAN Group to provide capital, mentoring, and market access to its portfolio companies.
What's next for Svastek?
With this recent strategic investment, Svastek is poised to transition from its initial development phase into a broader commercialization strategy. The capital will likely be deployed to scale manufacturing capabilities, conduct further clinical validation, and navigate regulatory pathways for international market entry. As the company continues to refine its NIV technology, the focus will shift toward establishing strategic partnerships with major hospital networks and critical care facilities. This expansion phase is critical for Svastek to solidify its market position and demonstrate the long-term scalability of its innovative respiratory care platform.
See full Svastek company page
